MCID: PYD001
MIFTS: 51

Pyoderma Gangrenosum malady

Categories: Rare diseases, Skin diseases, Bone diseases

Aliases & Classifications for Pyoderma Gangrenosum

About this section
Sources:
11Disease Ontology, 13DISEASES, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 39MeSH, 40MESH via Orphanet, 48NIH Rare Diseases, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Pyoderma Gangrenosum:

Name: Pyoderma Gangrenosum 11 48 54 50 39 13 68

Characteristics:

Orphanet epidemiological data:

54
pyoderma gangrenosum:
Prevalence: 1-9/100000 (United States),1-9/1000000 (United Kingdom),1-9/1000000 (Spain),1-9/1000000 (Worldwide); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy

Classifications:



External Ids:

Disease Ontology11 DOID:8553
ICD1030 L88
ICD9CM32 686.01
MeSH39 D017511
SNOMED-CT62 74578003
Orphanet54 ORPHA48104
MESH via Orphanet40 D017511
UMLS via Orphanet69 C0085652
ICD10 via Orphanet31 L88

Summaries for Pyoderma Gangrenosum

About this section
NIH Rare Diseases:48 Pyoderma gangrenosum is a rare, destructive inflammatory skin disease of which a painful nodule or pustule breaks down to form a progressively enlarging ulcer. lesions may occur either in the absence of any apparent underlying disorder or in association with other diseases, such as ulcerative colitis, crohn's disease, polyarthritis (an inflammation of several joints together), gammopathy, vasculitis, leukemia, and other conditions. each year in the united states, pyoderma gangrenosum occurs in about 1 person per 100,000 people. pyoderma gangrenosum belongs to a group of autoinflammatory skin diseases called neutrophilic dermatoses. neutrophils are a type of white blood cell or leukocyte which form an early line of defense against bacterial infections. ulcerations associated with pyoderma gangrenosum may occur after trauma or injury to the skin, a process called pathergy. treatment involves wound care and the use of anti-inflammatory agents, including antibiotics, corticosteroids, immunosuppressants, and biologics.  last updated: 8/15/2016

MalaCards based summary: Pyoderma Gangrenosum is related to collagenous colitis and rheumatoid arthritis, and has symptoms including Array, Array and Array. An important gene associated with Pyoderma Gangrenosum is PSTPIP1 (Proline-Serine-Threonine Phosphatase Interacting Protein 1), and among its related pathways are Canonical NF-kappaB pathway and Overview of nanoparticle effects. The drugs clofazimine and sulfapyridine pwdr have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and breast, and related mouse phenotypes are hematopoietic system and skeleton.

Wikipedia:71 Pyoderma gangrenosum is a condition that causes tissue to become necrotic, causing deep ulcers that... more...

Related Diseases for Pyoderma Gangrenosum

About this section

Diseases related to Pyoderma Gangrenosum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 240)
idRelated DiseaseScoreTop Affiliating Genes
1collagenous colitis30.0CXCL8, NOD2, TNF
2rheumatoid arthritis29.9CXCL8, IL1R1, ITGB2, TNF
3prostatitis29.6IL1R1, NLRP3
4invasive aspergillosis29.6MEFV, NLRP3
5skin conditions29.4CXCL8, NLRP3, TNF
6pyogenic sterile arthritis, pyoderma gangrenosum, and acne12.4
7pyogenic arthritis, pyoderma gangrenosum and acne12.3
8pyoderma gangrenosum-acne-suppurative hidradenitis syndrome12.1
9pyoderma11.7
10crohn's disease11.5
11ileocolitis11.1
12polydactyly, postaxial, types a1 and b11.1
13colitis10.5
14ulcerative colitis10.5
15acne10.4
16inflammatory bowel disease10.4
17arthritis10.4
18radial ray agenesis10.3IL1R1, PSTPIP1
19nemaline myopathy 1, autosomal dominant or recessive10.3PSTPIP1, TNF
20hidradenitis10.2
21myeloid neoplasms associated with pdgfrb rearrangement10.2MEFV, TNF
22tau syndrome10.2MEFV, TNF
23lymphoma10.2
24dermatosis papulosa nigra10.2NOD2, TNF
25myelodysplastic syndrome10.2
26amyotrophic lateral sclerosis type 510.2NOD2, TNF
27tetanus10.2MEFV, TNF
28psoriatic arthritis10.2NOD2, TNF
29conidiobolomycosis10.2CXCL8, TNF
30thymic neuroendocrine carcinoma10.2CXCL8, TNF
31female reproductive system disease10.2NOD2, TNF
32coronary arterial fistulas10.2CXCL8, NOD2
33acute gonococcal cystitis10.2CXCL8, NOD2
34handl syndrome10.2CXCL8, TNF
35nephronophthisis 1, juvenile10.1CXCL8, TNF
36plantar wart10.1CXCL8, TNF
37urethral intrinsic sphincter deficiency10.1ITGB2, TNF
38esophagus lymphoma10.1CXCL8, TNF
39benign neonatal seizures10.1IL1R1, MEFV, TNF
40hidradenitis suppurativa10.1
41vasculitis10.1
42functional gastric disease10.1IL1R1, NOD2, TNF
43esophageal candidiasis10.1IL1R1, NOD2, TNF
44ulcerative proctitis10.1CXCL8, TNF
45breast reconstruction10.1
46hepatitis10.1
47subcorneal pustular dermatosis10.1
48bare lymphocyte syndrome, type i10.1CXCL8, IL1R1, TNF
49dermatomycosis10.1MEFV, TNF
50strawberry gallbladder10.1CXCL8, MEFV, TNF

Graphical network of the top 20 diseases related to Pyoderma Gangrenosum:



Diseases related to pyoderma gangrenosum

Symptoms & Phenotypes for Pyoderma Gangrenosum

About this section

Human phenotypes related to Pyoderma Gangrenosum:

 54 64 (show all 15)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 atrophic scars64 54 Frequent (79-30%) HP:0001075
2 rheumatoid arthritis64 54 Frequent (79-30%) HP:0001370
3 fever64 54 Very frequent (99-80%) HP:0001945
4 inflammation of the large intestine64 54 Frequent (79-30%) HP:0002037
5 arthralgia64 54 Very frequent (99-80%) HP:0002829
6 myelodysplasia64 54 Frequent (79-30%) HP:0002863
7 myalgia64 54 Very frequent (99-80%) HP:0003326
8 abnormal blistering of the skin64 54 Occasional (29-5%) HP:0008066
9 increased antibody level in blood64 54 Frequent (79-30%) HP:0010702
10 myeloid leukemia64 54 Frequent (79-30%) HP:0012324
11 myositis64 54 Very frequent (99-80%) HP:0100614
12 papule64 54 Very frequent (99-80%) HP:0200034
13 skin vesicle64 54 Occasional (29-5%) HP:0200037
14 pustule64 54 Frequent (79-30%) HP:0200039
15 skin ulcer64 54 Very frequent (99-80%) HP:0200042

MGI Mouse Phenotypes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053978.5IL1R1, ITGB2, MEFV, NLRP3, NOD2, PSTPIP1
2MP:00053908.0IL1R1, ITGB2, MEFV, NLRP3, NOD2, TNF
3MP:00053877.6IL1R1, ITGB2, MEFV, MMP10, NLRP3, NOD2

Drugs & Therapeutics for Pyoderma Gangrenosum

About this section

Drugs for Pyoderma Gangrenosum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Minocyclineapproved, investigationalPhase 323110118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
Alti-Minocycline
Apo-Minocycline
Arestin
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
Dynacin
Gen-Minocycline
HMS2090D03
HSDB 3130
Klinomycin
 
LMPK07000002
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline (USAN/INN)
Minocycline HCl
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
Minocyn
Minomycin
NCGC00178854-01
NSC 141993
NSC141993
Novo-Minocycline
Solodyn
UNII-FYY3R43WGO
Vectrin
Vectrin (Hydrochloride)
minociclinum
minocycline
nchembio.559-comp1
2Anti-Infective AgentsPhase 322062
3Anti-Bacterial AgentsPhase 311226
4Pharmaceutical SolutionsPhase 3, Phase 28192
5
Tacrolimusapproved, investigationalPhase 21102104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
6Immunosuppressive AgentsPhase 213086
7Antirheumatic AgentsPhase 210956
8ImmunoglobulinsPhase 2, Phase 16394
9Calcineurin InhibitorsPhase 21622
10AntibodiesPhase 2, Phase 16394
11Antibodies, MonoclonalPhase 2, Phase 14039
12
Infliximabapproved392170277-31-3
Synonyms:
 
Ig gamma-1 chain C region
Remicade
13Dermatologic Agents5806
14Gastrointestinal Agents8402

Interventional clinical trials:

(show all 16)
idNameStatusNCT IDPhase
1Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot StudyUnknown statusNCT00203697Phase 3
2An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedNCT02326740Phase 3
3An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedNCT02315417Phase 3
4A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma GangrenosumTerminatedNCT02318914Phase 3
5Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma GangrenosumCompletedNCT01882504Phase 2
6A Phase II Open Label Study of Xilonix in Subjects With Pyoderma GangrenosumCompletedNCT01965613Phase 2
7Canakinumab for Pyoderma GangrenosumCompletedNCT01302795Phase 2
8Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's DiseaseCompletedNCT01233570Phase 2
9Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma GangrenosumRecruitingNCT02733094Phase 1, Phase 2
10An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma GangrenosumRecruitingNCT03137160Phase 2
11Efficacy and Safety of APD334 in Patients With Pyoderma GangrenosumRecruitingNCT03072953Phase 2
12Safety and Efficacy Study of Humira in Treatment of Pyoderma GangrenosumWithdrawnNCT00730717Phase 2
13Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma GangrenosumWithdrawnNCT00690846Phase 2
14Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic FactorsUnknown statusNCT00933296
15Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel DiseaseCompletedNCT00791557
16Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin DiseasesRecruitingNCT01952275

Search NIH Clinical Center for Pyoderma Gangrenosum

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: pyoderma gangrenosum

Genetic Tests for Pyoderma Gangrenosum

About this section

Anatomical Context for Pyoderma Gangrenosum

About this section

MalaCards organs/tissues related to Pyoderma Gangrenosum:

36
Skin, Neutrophil, Breast, Bone, T cells, Myeloid, Lung

Publications for Pyoderma Gangrenosum

About this section

Articles related to Pyoderma Gangrenosum:

(show top 50)    (show all 698)
idTitleAuthorsYear
1
An Unusual Association of Chronic Recurrent Multifocal Osteomyelitis, Pyoderma Gangrenosum, and Takayasu Arteritis. (28042129)
2017
2
Pyoderma Gangrenosum, Acne and Suppurative Hidradenitis Syndrome Treated with Granulocyte and Monocyte Adsorption Apheresis. (27384061)
2016
3
Treatment of refractory pyoderma gangrenosum with infliximab in a 17-month-old boy. (27617462)
2016
4
Pyoderma gangrenosum and necrotizing fasciitis-like opportunistic invasive cutaneous fungal infection. (27126743)
2016
5
Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: The Mayo Clinic experience, 1996 through 2013. (27473454)
2016
6
Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis. (27799888)
2016
7
Facial Pyoderma Gangrenosum Presenting With Cranial Nerve VII Palsy and Cicatricial Ectropion. (27893584)
2016
8
Pediatric pyoderma gangrenosum: is it just big wounds on little adults? (27916349)
2016
9
High level of serum human interleukin-18 in a patient with pyogenic arthritis, pyoderma gangrenosum and acne syndrome. (27505688)
2016
10
Pyoderma gangrenosum of the eyelid. (27085278)
2016
11
Postoperative Pyoderma Gangrenosum: AA Clinical Review of Published Cases. (27489052)
2016
12
Gene Therapy for Pyoderma Gangrenosum: Optimal Transfection Conditions and Effect of Drugs on Gene Delivery in the HaCaT Cell Line Using Cationic Liposomes. (27159975)
2016
13
Post Surgical Pyoderma Gangrenosum in flap surgery: diagnostic clues and treatment recommendations. (27938245)
2016
14
Pyoderma gangrenosum with extensive pulmonary involvement. (27658239)
2016
15
Pyoderma gangrenosum and its syndromic forms: Evidence for a link with autoinflammation. (27106250)
2016
16
Successful Treatment of Pyoderma Gangrenosum after Augmentation Mastopexy Using Vacuum Therapy. (27975008)
2016
17
Severe pyoderma gangrenosum in association with a flame burn. (27583260)
2016
18
Intralesional methotrexate as an adjuvant treatment for pyoderma gangrenosum: A case report. (27451930)
2016
19
Severe Bilateral Lower Extremity Pyoderma Gangrenosum. (27980702)
2016
20
Pyoderma gangrenosum after trauma in a dog. (27108868)
2016
21
Successful Treatment of Pyoderma Gangrenosum with Cryoglobulinemia and Hepatitis C. (27345376)
2016
22
Delayed diagnosis of bullous pyoderma gangrenosum with acute myelogenous leukemia. (27811462)
2016
23
Autoinflammation in pyoderma gangrenosum and its syndromic form PASH. (27943240)
2016
24
Pyoderma gangrenosum associated with mantle cell lymphoma. (27559522)
2016
25
Pyoderma gangrenosum mimicking mediastinitis after cardiac surgery: a case study. (27286670)
2016
26
Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case. (27051318)
2016
27
Bullous Pyoderma Gangrenosum With Subungual Involvement Associated With Ulcerative Colitis. (27893467)
2016
28
Unusual cause of breast wound: postoperative pyoderma gangrenosum. (27444684)
2016
29
High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum. (27502191)
2016
30
Pyoderma gangrenosum: A clinico-epidemiological study. (27549869)
2016
31
Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. (27864925)
2016
32
Hyperbaric Oxygen Therapy for the Adjunctive Treatment of Pyoderma Gangrenosum: A Case Report. (27192719)
2016
33
Successful treatment of large refractory pyoderma gangrenosum-like presentation of granulomatosis with polyangiitis with rituximab. (27126548)
2016
34
Concomitant Pyoderma Gangrenosum and Erythema Nodosum in a Patient With Ulcerative Colitis. (27474109)
2016
35
Ocular pyoderma gangrenosum: A systematic review. (27836332)
2016
36
Pyoderma Gangrenosum-A New Manifestation of Wilson Disease? (27194899)
2016
37
Pyoderma Gangrenosum in the Urologist Clinic. (27867335)
2016
38
The diagnosis you wish you had never operated on: Pyoderma gangrenosum misdiagnosed as necrotizing fasciitis-a case report. (27875063)
2016
39
Pyoderma gangrenosum associated with alitretinoin therapy. (27051854)
2016
40
Cutaneous malakoplakia masquerading as pyoderma gangrenosum. (27524799)
2016
41
Pyoderma gangrenosum with spleen involvement. Review of the literature and case report. (27900062)
2016
42
Double Jeopardy: Autoimmune Myelofibrosis with Pyoderma Gangrenosum. (27401951)
2016
43
Extensive Pyoderma Gangrenosum Associated With Granulomatosis With Polyangiitis With Both Responsive to Rituximab. (27660945)
2016
44
Multiple Pyoderma Gangrenosum Ulcers Associated with Cocaine Abuse. (28003907)
2016
45
Pyogenic Arthritis, Pyoderma Gangrenosum, Acne, Suppurative Hidradenitis (PA-PASH) Syndrome: An Atypical Presentation of a Rare Syndrome. (27530224)
2016
46
Treatment of Pyoderma Gangrenosum - Retrospective Multicenter Analysis of 121 Patients. (27060666)
2016
47
Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study. (27502313)
2016
48
Postsurgical pyoderma gangrenosum successfully treated with cyclosporine. (27852992)
2016
49
Pyoderma gangrenosum in a caesarean wound following caesarean section with late occurrence of pyoderma gangrenosum of the breast. (27435999)
2016
50
Total hip arthroplasty for femoral neck fracture with pyoderma gangrenosum patient: A case report. (28012329)
2016

Variations for Pyoderma Gangrenosum

About this section

Expression for genes affiliated with Pyoderma Gangrenosum

About this section
Search GEO for disease gene expression data for Pyoderma Gangrenosum.

Pathways for genes affiliated with Pyoderma Gangrenosum

About this section

Pathways related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 21)
idSuper pathwaysScoreTop Affiliating Genes
19.8NOD2, TNF
29.6CXCL8, TNF
39.6CXCL8, TNF
49.5IL1R1, NLRP3
59.4MEFV, NLRP3, NOD2
69.2ITGB2, NOD2, TNF
79.1CXCL8, ITGB2, TNF
89.1CXCL8, ITGB2, TNF
99.1CXCL8, ITGB2, TNF
109.1CXCL8, ITGB2, TNF
11
Show member pathways
9.1CXCL8, IL1R1, TNF
129.1CXCL8, IL1R1, TNF
13
Show member pathways
9.1CXCL8, IL1R1, TNF
149.1CXCL8, IL1R1, TNF
159.1CXCL8, IL1R1, TNF
16
Show member pathways
9.1MEFV, NLRP3, NOD2, PSTPIP1
178.7CXCL8, ITGB2, NLRP3, TNF
188.6CXCL8, IL1R1, ITGB2, TNF
19
Show member pathways
8.3CXCL8, IL1R1, ITGB2, NOD2, TNF
20
Show member pathways
7.7CXCL8, IL1R1, MEFV, NLRP3, NOD2, PSTPIP1
21
Show member pathways
7.2CXCL8, IL1R1, ITGB2, MEFV, NLRP3, NOD2

GO Terms for genes affiliated with Pyoderma Gangrenosum

About this section

Cellular components related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cell surfaceGO:00099868.7IL1R1, ITGB2, NOD2, TNF

Biological processes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1detection of biotic stimulusGO:000959510.5NLRP3, NOD2
2embryonic digestive tract developmentGO:004856610.4CXCL8, TNF
3positive regulation of interleukin-8 productionGO:003275710.4NOD2, TNF
4positive regulation of interleukin-1 beta secretionGO:005071810.3NLRP3, NOD2
5cellular extravasationGO:004512310.3ITGB2, TNF
6positive regulation of NIK/NF-kappaB signalingGO:190122410.3NOD2, TNF
7positive regulation of type 2 immune responseGO:000283010.3NLRP3, NOD2
8receptor internalizationGO:003162310.0CXCL8, ITGB2
9cellular response to lipopolysaccharideGO:007122210.0CXCL8, NLRP3, TNF
10immune system processGO:00023769.8MEFV, NLRP3, NOD2, PSTPIP1
11negative regulation of inflammatory responseGO:00507289.7MEFV, MVK, NLRP3
12innate immune responseGO:00450879.7MEFV, NLRP3, NOD2, PSTPIP1
13defense responseGO:00069529.6CXCL8, NLRP3, NOD2, TNF
14positive regulation of NF-kappaB transcription factor activityGO:00510929.4ITGB2, NLRP3, NOD2, TNF
15regulation of inflammatory responseGO:00507279.2IL1R1, NLRP3, NOD2
16inflammatory responseGO:00069548.8CXCL8, ITGB2, MEFV, NLRP3, PSTPIP1, TNF

Molecular functions related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1peptidoglycan bindingGO:00428349.7NLRP3, NOD2

Sources for Pyoderma Gangrenosum

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet